AR086236A1 - Inhibidores de la tirosina quinasa de bazo (syk) que contienen aminopiridina - Google Patents

Inhibidores de la tirosina quinasa de bazo (syk) que contienen aminopiridina

Info

Publication number
AR086236A1
AR086236A1 ARP120101538A ARP120101538A AR086236A1 AR 086236 A1 AR086236 A1 AR 086236A1 AR P120101538 A ARP120101538 A AR P120101538A AR P120101538 A ARP120101538 A AR P120101538A AR 086236 A1 AR086236 A1 AR 086236A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halo
fluoroalkyl
phenyl
Prior art date
Application number
ARP120101538A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR086236A1 publication Critical patent/AR086236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

También proporciona composiciones farmacéuticas que comprende dichos compuestos y procedimientos para usar los compuestos para tratar enfermedades o afecciones mediadas por la tirosina quinasa de bazo (Syk).Reivindicación 1: Un compuesto de fórmula (1) o una de sus sales farmacéuticamente aceptables, en la que: R1 se selecciona del grupo que consiste en: (i) -alquilo C1-3; (ii) fluoroalquilo; (iii) -CH2OR1a, en la que R1a se selecciona del grupo que consiste en H y alquilo C1-6; (iv) -N(R1b)2, en la que cada aparición de R1b se selecciona del grupo que consiste en H y alquilo C1-3 o dos R1b junto con el átomo de N al que están unidos forman un grupo de fórmula (2), en la que r es 1, 2, 3 ó 4; (v) -O-(alquilo C1-3); (vi) -N(H)C(O)-(alquilo C1-3); (vii) halo; (viii) H; y (ix) morfolinilo; R2 es -OH, -O-(alquilo C1-3), -N(R2a)2, -N(R2a)C(O)-R2b o -F; en la que R2a se selecciona del grupo que consiste en H, alquilo C1-3; y R2b es alquilo C1-6; R3 es -CO2R3a, -CH2CO2R3a, -CH2CH2CO2R3a, tetrazol, -C(O)N(R3b)2, -CH2OH, H, halo, -OH-alquilo C1-6, -O-(alquilo C1-3), -N(R3b)2, -CN, -C(O)N(H)S(O)2R3c, -C(O)-N(H)(R3d), -C(O)N(H)C(O)R3a, -P(O)(OR3b)2 o -B(OH)2; donde R3a se selecciona entre el grupo que cosiste en H y alquilo C1-6; donde cada R3b se selecciona independientemente entre el grupo que consiste en H y alquilo C1-3; donde R3c se selecciona entre el grupo que consiste en alquilo C1-3, fluoroalquilo C1-3, cicloalquilo C3-6 y fenilo, donde dicho fenilo está sin sustituir o sustituido con uno o dos alquilo C1-3; donde R3d se selecciona entre el grupo que consiste en -CN, -O-(alquilo C1-3) y tetrazol; R4 es -CO2R4a, CH2CO2R4a, -CH2CH2CO2R4a, tetrazol, -C(O)N(R4b)2, -CH2OH, H, halo, -OH, alquilo C1-6, -O-(alquilo C1-3), -N(R4b)2, -CN, C(O)N(H)S(O)2R4c, -C(O)-N(H)(R4d), C(O)N(H)C(O)R4a, -P(O)(OR4b)2 o -B(OH)2; donde R4a se selecciona entre el grupo que consiste en H y alquilo C1-6; donde cada R4b se selecciona independientemente entre el grupo que consiste en H y alquilo C1-3; donde R4c se selecciona entre el grupo que consiste en alquilo C1-3, fluoroalquilo C1-3, cicloalquilo C3-6 y fenilo, donde dicho fenilo está sin sustituir o sustituido con uno o dos alquilo C1-3; donde R4d se selecciona entre el grupo que consiste en -CN, -O-(alquilo C1-3) y tetrazol; R5 es -CO2R5a, CH2CO2R5a, -CH2CH2CO2R5a, tetrazol, -C(O)N(R5b)2, -CH2OH, H, halo, -OH, alquilo C1-6, -O-(alquilo C1-3), -N(R5b)2, -CN, C(O)N(H)S(O)2R5c, -C(O)-N(H)(R5d), -C(O)N(H)C(O)R5a, -P(O)(OR5b)2 o -B(OH)2; donde R5a se selecciona entre el grupo que consiste en H y alquilo C1-6; donde cada R5b se selecciona independientemente entre el grupo que consiste en H y alquilo C1-3; donde R5c se selecciona entre el grupo que consiste en alquilo C1-3, fluoroalquilo C1-3, cicloalquilo C3-6 y fenilo, donde dicho fenilo está sin sustituir o sustituido con uno o dos alquilo C1-3; donde R5d se selecciona entre el grupo que consiste en -CN, -O-(alquilo C1-3) y tetrazol; R6 se selecciona entre el grupo que consiste en: (i) alquilo C1-6; (ii) fluoroalquilo C1-3; (iii) -O-(alquilo C1-6); (iv) -O-(fluoroalquilo C1-3); (v) -R6a, donde R6a se selecciona entre el grupo que consiste en: (a) cicloalquilo C3-6; (b) un grupo de la fórmula (3), en la que m es 1, 2, 3 ó 4; (c) un grupo de la formula (4), donde R6a1 es H, alquilo C1-3, o -CH2CH2NH2; y (d) un heteroarilo de 5 a 6 miembros que contiene 1 a 3 heteroátomos seleccionados entre el grupo que consiste en N, O y S; donde R6a está sin sustituir o sustituido con 1 a 3 restos R6a2 seleccionados entre el grupo que consiste en halo y alquilo C1-3; (vi) -O-R6b, donde R6b se selecciona entre el grupo que consiste en: (a) cicloalquilo C3-6; y (b) un grupo de la fórmula (5), en la que p es 0, 1 ó 2, y q es 1, 2 ó 3; donde R6b está sin sustituir o sustituido con 1 a 2 restos R6b1 seleccionados entre el grupo que consiste en flúor y alquilo C1-3; (vii) -N(R6c)2, donde cada aparición de R6c se selecciona entre el grupo que consiste en H y alquilo C1-3; (viii) -N(H)C(O)-(alquilo C1-3); (ix) -N(H)C(O)O-(alquilo C1-3); (x) -NHC(O)N(R6d)2, donde cada R6d es H o alquilo C1-3; (xi) halo; y (xii) H; R7 es H o halo; R8 es H o halo; R9 es H o halo; y n es 0, 1 ó 2.
ARP120101538A 2011-05-04 2012-05-02 Inhibidores de la tirosina quinasa de bazo (syk) que contienen aminopiridina AR086236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161482508P 2011-05-04 2011-05-04

Publications (1)

Publication Number Publication Date
AR086236A1 true AR086236A1 (es) 2013-11-27

Family

ID=47108006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101538A AR086236A1 (es) 2011-05-04 2012-05-02 Inhibidores de la tirosina quinasa de bazo (syk) que contienen aminopiridina

Country Status (13)

Country Link
US (2) US8796310B2 (es)
EP (1) EP2704571B1 (es)
JP (1) JP5934782B2 (es)
KR (1) KR20140025500A (es)
CN (1) CN103619170B (es)
AR (1) AR086236A1 (es)
AU (1) AU2012250958B8 (es)
BR (1) BR112013028430A2 (es)
CA (1) CA2834043A1 (es)
MX (1) MX2013012776A (es)
RU (1) RU2612217C2 (es)
TW (1) TW201247663A (es)
WO (1) WO2012151137A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
KR20130130729A (ko) * 2010-10-28 2013-12-02 니뽄 신야쿠 가부시키가이샤 피리딘 유도체 및 의약
CN103619170B (zh) 2011-05-04 2016-07-06 默沙东公司 含有氨基-吡啶的脾酪氨酸激酶(syk)抑制剂
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
CN103619172A (zh) 2011-05-10 2014-03-05 默沙东公司 作为syk抑制剂的氨基嘧啶
JP6267193B2 (ja) * 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
EP2916836A4 (en) * 2012-11-07 2016-08-03 Merck Sharp & Dohme AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
EP2934525B1 (en) * 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
US12102626B2 (en) * 2018-12-27 2024-10-01 Nexys Therapeutics, Inc. (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer
EP3699167A1 (en) * 2019-02-22 2020-08-26 Sanofi Process for preparing methyl 1-benzosuberone-7-carboxylate
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112370455A (zh) * 2020-10-19 2021-02-19 济南大学 一种磺酰胺衍生物作为α-葡萄糖苷酶抑制剂及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
CA2537141A1 (en) 2003-09-02 2005-03-10 Merck And Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
RU2363699C2 (ru) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
ZA200707227B (en) * 2005-02-28 2009-08-26 Japan Tobacco Inc Novel aminopyridine compound with syk inhibitory activity
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
WO2006129100A1 (en) * 2005-06-03 2006-12-07 Glaxo Group Limited Novel compounds
WO2008106202A1 (en) 2007-02-27 2008-09-04 Housey Gerard M Theramutein modulators
MA33926B1 (fr) * 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
CN103619170B (zh) 2011-05-04 2016-07-06 默沙东公司 含有氨基-吡啶的脾酪氨酸激酶(syk)抑制剂
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
CN103619172A (zh) 2011-05-10 2014-03-05 默沙东公司 作为syk抑制剂的氨基嘧啶

Also Published As

Publication number Publication date
EP2704571A1 (en) 2014-03-12
RU2013153540A (ru) 2015-06-10
WO2012151137A1 (en) 2012-11-08
EP2704571B1 (en) 2020-04-22
CN103619170B (zh) 2016-07-06
US20130090309A1 (en) 2013-04-11
US8796310B2 (en) 2014-08-05
AU2012250958A1 (en) 2013-10-31
CN103619170A (zh) 2014-03-05
AU2012250958B2 (en) 2016-09-15
BR112013028430A2 (pt) 2017-08-01
JP5934782B2 (ja) 2016-06-15
AU2012250958B8 (en) 2017-02-09
JP2014513120A (ja) 2014-05-29
TW201247663A (en) 2012-12-01
CA2834043A1 (en) 2012-11-08
RU2612217C2 (ru) 2017-03-03
MX2013012776A (es) 2013-11-21
AU2012250958A8 (en) 2017-02-09
KR20140025500A (ko) 2014-03-04
EP2704571A4 (en) 2014-10-29
US20140323440A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
AR086236A1 (es) Inhibidores de la tirosina quinasa de bazo (syk) que contienen aminopiridina
ES2543567T3 (es) Métodos de utilización de inhibidores de ALK
AR090539A1 (es) COMPUESTOS INHIBIDORES DE b LACTAMASA
PE20160044A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
PE20220502A1 (es) Compuestos utiles como inhibidores de cinasa
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6321170A2 (es) Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
ES2667477T3 (es) Compuestos heterobiciclo-sustituidos-[1,2,4]triazolo[1,5-c]quinazolin-5-amina adecuados para el tratamiento o la prevención de trastornos del sistema nervioso central
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
AR086958A1 (es) Antagonistas de trpv4
PE20141160A1 (es) Metodos para preparar analogos nucleotidicos antivirales
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
AR085425A1 (es) Inhibidores de la glucosilceramida sintasa
AR073136A1 (es) Compuestos de pirrol
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
RU2012129930A (ru) Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
AR082138A1 (es) 1-hidroxiimino-3-fenil-propanos
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
CO6801736A2 (es) Derivados heterocíclicos de amina
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras

Legal Events

Date Code Title Description
FB Suspension of granting procedure